Pilot Study: New Aqueous Extracts of the Mistletoe (Viscum Album L.) Plant, Diminish In Vitro Cell Proliferation of The NSCLC Cell Line with EGFR Mutations HCC 827

Abstract

Non-small cell lung adenocarcinoma with EGFR mutations continues to be a vexing problem due to the ability of the cancer to rapidly develop drug resistance. In vitro studies with the non-small cell lung adenocarcinoma cell line HCC827 (with an acquired mutation in the EGFR tyrosine kinase domain, E746 - A750 deletion) are relevant to the finding of increasingly effective treatments. Pharmaceutically processed, extracts of mistletoe, Viscum album Loranthaceae, have been shown since the 1920’s to have potential in cancer therapy. They are currently the most frequently used natural preparations in complementary cancer treatments. In this pilot study we demonstrate that newly prepared standardized extractions of mistletoe (Viscum album, L.), from different host trees, are shown to significantly diminish the cell proliferation of the HCC 827 cell line.

Keywords: Mistletoe; Viscum album; Iscador; HCC827; non-small cell lung cancer; Adenocarcinoma; EGFR; Extracts; Lili Kolisko; Rudolf Steiner

Abbreviations: V: Viscum, NSCLC: Non-Small Cell Lung Cancer; ADC: Adenocarcinoma

External link to article: https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.556160.pdf

Citation: Rentea, R., Kamsler, M., & Mueller, M. (2023). Pilot Study: New Aqueous Extracts of the Mistletoe (Viscum Album L.) Plant, Diminish In Vitro Cell Proliferation of The NSCLC Cell Line with EGFR Mutations HCC 827. Cancer Therapy & Oncology International Journal, 25(1). https://doi.org/10.19080/CTOIJ.2023.25.556160